Comparing jurisdiction-specific pharmaco-economic evaluations using medical purchasing power parities
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Comparing jurisdiction-specific pharmaco-economic evaluations using medical purchasing power parities
Authors
Keywords
-
Journal
JOURNAL OF MEDICAL ECONOMICS
Volume 24, Issue sup1, Pages 34-41
Publisher
Informa UK Limited
Online
2021-12-06
DOI
10.1080/13696998.2021.2007705
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Economic Evaluation for USA of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer
- (2018) Mahdi Gharaibeh et al. PHARMACOECONOMICS
- Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
- (2018) Angela Stainthorpe et al. PHARMACOECONOMICS
- Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer
- (2018) Mahdi Gharaibeh et al. PHARMACOECONOMICS
- An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study
- (2018) Carlo Lazzaro et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cost-Effectiveness Analysis of Systemic Therapies in Advanced Pancreatic Cancer in the Canadian Health Care System
- (2017) Doug Coyle et al. VALUE IN HEALTH
- Current standards and new innovative approaches for treatment of pancreatic cancer
- (2016) Thierry Conroy et al. EUROPEAN JOURNAL OF CANCER
- Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer
- (2016) Mahdi Gharaibeh et al. JOURNAL OF MEDICAL ECONOMICS
- Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer
- (2015) M Gharaibeh et al. BRITISH JOURNAL OF CANCER
- A Cost-Utility Analysis Of Nab-Paclitaxel (Abraxane) Plus Gemcitabine In Metastatic Pancreatic Cancer In Slovak Republic
- (2015) R Stetka et al. VALUE IN HEALTH
- Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study
- (2015) Alfredo Carrato et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Economic Evaluation of NAB-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone for The Management of Metastatic Pancreatic Cancer in Greece
- (2014) V. Fragoulakis et al. VALUE IN HEALTH
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Transferability of Economic Evaluations Across Jurisdictions: ISPOR Good Research Practices Task Force Report
- (2009) Michael Drummond et al. VALUE IN HEALTH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More